Results 41 to 50 of about 17,756 (247)

First-in-Human Study of the CD123 NK Cell Engager SAR443579 in Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia or High Risk-Myelodysplasia: Updated Safety, Efficacy, Pharmacokinetics and Pharmacodynamics

Blood, 2023
Introduction: SAR443579 (SAR'579) is a trifunctional anti-CD123 NKp46xCD16 natural killer cell engager, facilitating the formation of a cytolytic synapse between natural killer (NK)-cells and CD123-positive tumor cells leading to NK-cell activation and
A. Bajel, S. Garciaz, Pinkal M. Desai, G. Huls, A. Maiti, M. Jongen-Lavrencic, N. Boissel, S. de Botton, D. D. de Leeuw, Shaun A Fleming, C. Zwaan, Martha L. Arellano, D. Avigan, Jennifer N. Saultz, Ioannis Mantzaris, K. Jensen, Timothy Wagenaar, Gu Mi, Samira Ziti-Ljajic, D. Draganov, G. Abbadessa, A. Stein   +21 more
semanticscholar   +1 more source

Pivekimab Sunirine (PVEK, IMGN632), a CD123-Targeting Antibody-Drug Conjugate, in Combination with Azacitidine and Venetoclax in Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood, 2023
Background In unfit patients (pts) with newly diagnosed (ND) AML, long-term survival remains short (mOS 14.7 months) despite improved responses (CR 37% and CR/CRi 66%) with azacitidine (AZA) and venetoclax (VEN) (VIALE-A, DiNardo NEJM 2020).
N. Daver, P. Montesinos, Jessica K. Altman, E. Wang, G. Martinelli, G. Roboz, K. Begna, Paresh Vyas, M. Lunghi, U. Platzbecker, Patrick W. Burke, Roland B. Walter, A. Advani, S. Garciaz, L. Gastaud, D. Sallman, Naveen Pemmaraju, Laura Torres, Yasmin M. Abaza, O. Chan, H. Kantarjian, Benjamin Oshrine, Yi-Ning Du, Kara E. Malcolm, K. Sweet   +24 more
semanticscholar   +1 more source

High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations

Frontiers in Oncology, 2021
BackgroundAberrant expression of CD123 (IL-3Rα) was observed in various hematological malignancies including acute lymphoblastic leukemia (ALL), which is the most common malignancy in childhood.
Zhiheng Li, Zhiheng Li, Zhiheng Li, Xinran Chu, Li Gao, Jing Ling, Peifang Xiao, Jun Lu, Yi Wang, Hailong He, Jianqin Li, Yixin Hu, Jie Li, Jian Pan, Sheng Xiao, Shaoyan Hu   +15 more
doaj   +1 more source

Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm.

Clinical Lymphoma, Myeloma & Leukemia, 2023
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy of the dendritic cell lineage that affects patients of all ages, though the incidence appears to be highest in patients over the age of 60 years.
Naveen Pemmaraju, Eric Deconinck, Priyanka Mehta, Irwin Walker, M. Herling, F. Garnache-Ottou, N. Gabarin, C. Campbell, J. Duell, Yakir Moshe, T. Mughal, M. Mohty, E. Angelucci   +12 more
semanticscholar   +1 more source

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

OncoImmunology, 2021
Chimeric antigen receptor T cells (CAR-T) targeting CD19 have achieved significant success in patients with B cell malignancies. To date, implementation of CAR-T in other indications remains challenging due to the lack of truly tumor-specific antigens as
Jan-Erik Meyer, Simon Loff, Josephine Dietrich, Johannes Spehr, Gabriel Jurado Jiménez, Malte von Bonin, Gerhard Ehninger, Marc Cartellieri, Armin Ehninger   +8 more
doaj   +1 more source

Generation and proof-of-concept for allogeneic CD123 CAR-Delta One T (DOT) cells in acute myeloid leukemia

Journal for ImmunoTherapy of Cancer, 2022
Background Chimeric antigen receptor (CAR)-T cells have emerged as a breakthrough treatment for relapse/refractory hematological tumors, showing impressive complete remission rates. However, around 50% of the patients relapse before 1-year post-treatment.
Diego Sánchez Martínez, N. Tirado, Sofia Mensurado, A. Martínez-Moreno, P. Romecín, Francisco Gutiérrez Agüera, D. V. Correia, B. Silva‐Santos, P. Menéndez   +8 more
semanticscholar   +1 more source

A Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood, 2023
Background Leukemic stem cells have high expression of CD123 compared to normal hematopoietic stem cells and is therefore a therapeutic target in multiple leukemias including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic ...
Daniel Nguyen, F. Ravandi, Sa A. Wang, J. Jorgensen, Wei Wang, K. Chien, G. Montalban-Bravo, G. Issa, A. Maiti, Yesid Alvarado Valero, N. Daver, C. Dinardo, E. Jabbour, T. Kadia, Naveen Pemmaraju, M. Yilmaz, Jaehyun Lee, Pavan Bachireddy, U. Popat, G. Garcia-Manero, H. Kantarjian, N. Short   +21 more
semanticscholar   +1 more source

Circulating IRF8-expressing CD123+CD127+ lymphoid progenitors: key players in human hematopoiesis

Trends in immunology, 2023
Lymphopoiesis is the process in which B, T, and innate lymphoid cells (ILC) develop from hematopoietic progenitors that exhibit early lymphoid priming.
Kai Liang, E. Laurenti, T. Taghon
semanticscholar   +1 more source

First Disclosure of AZD9829, a TOP1i-ADC Targeting CD123: Promising Preclinical Activity in AML Models with Minimal Effect on Healthy Progenitors

Blood, 2023
CD123 is a cell surface protein that is overexpressed in several hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with restricted expression in normal hematopoietic stem cells.
Dipannita Dutta, Pan Pan, Ryan Fleming, M. Andrade-Campos, E. Belova, Jennifer Wheeler, Patricia Cheung, Paul V. Santacroce, C. Daniels, Darrin Sabol, Brad L Jakubison, Benedicte Recolin, A. Dippel, Margaret Wey, Arthur Shaffer, E. Rosfjord, Elaine Hurt, Gullu Gorgun, Anas Younes, P. Sapra   +19 more
semanticscholar   +1 more source

Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia

Nature Communications, 2022
Acute myeloid leukemia (AML) is a disease with high incidence of relapse that is originated and maintained from leukemia stem cells (LSCs). Hematopoietic stem cells can be distinguished from LSCs by an array of cell surface antigens such as CD123, thus a
M. Sugita, R. Galetto, H. Zong, Nathan Ewing-Crystal, Vicenta Trujillo-Alonso, N. Mencia-Trinchant, Winnie Yip, Stéphanie Filipe, C. Lebuhotel, A. Gouble, D. Hassane, Julianne N. P. Smith, G. Roboz, M. Guzman   +13 more
semanticscholar   +1 more source